Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
| Autor: | Emilien Billon, Audrey Monneur, Delphine Perrot, A. M. Stoppa, Massimo Bocci, Lena Mescam, François Bertucci |
|---|---|
| Přispěvatelé: | Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment [SDV]Life Sciences [q-bio] Follicular lymphoma Gastroenterology lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Surgical oncology immune system diseases Internal medicine hemic and lymphatic diseases Immune suppression medicine Kaposi's sarcoma CD20 biology business.industry Research Kaposi sarcoma virus diseases Immunosuppression medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ulcerative colitis 3. Good health Oncology 030220 oncology & carcinogenesis biology.protein 030211 gastroenterology & hepatology Rituximab Sarcoma business medicine.drug |
| Zdroj: | CLINICAL SARCOMA RESEARCH CLINICAL SARCOMA RESEARCH, 2018, 8, ⟨10.1186/s13569-018-0097-7⟩ Clinical Sarcoma Research Clinical Sarcoma Research, Vol 8, Iss 1, Pp 1-8 (2018) |
| DOI: | 10.1186/s13569-018-0097-7⟩ |
| Popis: | Background Kaposi’s sarcoma is a low-grade mesenchymal angioproliferative tumor, most commonly observed in immunocompromised individuals, such as HIV-infected patients. Iatrogenic Kaposi’s sarcoma occurs in patients undergoing immunosuppressive therapies. Rituximab is a chimeric monoclonal antibody targeted against the pan B cell marker CD20. Because of its immunosuppressive effects through reduction of mature B-cells, it may exacerbate Kaposi’s sarcoma in HIV-positive patients. Rituximab-related Kaposi’s sarcomas have been previously reported in only two HIV-negative patients and were treated surgically. Case presentation Here, we report on a Kaposi’s sarcoma that developed under rituximab treatment in a HIV-negative 55-year-old patient treated for follicular lymphoma. The lesion developed during the maintenance rituximab therapy at the rectal level with an aspect of apparent ulcerative colitis, without any cutaneous lesion. The premature stop of rituximab led to the complete regression of Kaposi’s sarcoma, without any additional specific treatment. Conclusions To our knowledge, this is the third case of Kaposi’s sarcoma diagnosed under rituximab in a HIV-negative patient, the first one at the rectal level and the first one that completely regresses after stop of rituximab. This case raises awareness of iatrogenic Kaposi’s sarcoma in HIV-negative patients treated with rituximab, and further highlights the importance of immunosuppression in the pathophysiology of disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|